May 25, 2018· Comment from Association for Accessible Medicines (AAM)· FDA-2018-D-1067-0045
Comments from The Association for Accessible Medicines (AAM) on behalf of a strong consensus of our member companies, regarding Docket FDA-2018-D-1067: Evaluation of Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug and Cosmetic Act.